References
- Disease GIfCL. 2018 Global strategy for prevention, diagnosis and management of COPD; 2018. [cited 2018 Jul 30]. Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf
- Martinez FJ, Rabe KF, Calverley PMA, et al. Determinants of response to roflumilast in severe COPD: pooled analysis of two randomized trials. Am J Respir Crit Care Med. 2018;198(10):1268–1278.
- Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–866.
- Zeneca A. Roflumilast in chronic obstructive pulmonary disease (COPD) patients treated with fixed dose combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS). [cited 2018 Jul 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT01443845.
- Martinez FJ, Rabe KF, Sethi S, et al. Effect of roflumilast and inhaled corticosteroid/long-acting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial. Am J Respir Crit Care Med. 2016;194:559–567.
- DataPharm. DAXAS 500 micrograms film-coated tablets. 2018. [cited 2018 Jul 28]. Available from: https://www.medicines.org.uk/emc/product/5650/smpc.
- Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.
- Meltzer EO, Chervinsky P, Busse W, et al. Roflumilast for asthma: efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther. 2015;35:S20–S27.
- Rabe KF, Watz H, Baraldo S, et al. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. Lancet Respir Med. 2018;6:827–836.